Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Inc Ordinary Shares RNA
News
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
Avidity Biosciences Honors Rare Disease Day®
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity's stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments
Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership
Avidity Biosciences Gets Orphan-Drug Status for Muscular Dystrophy Treatment
Avidity Biosciences: FDA Eases Partial Clinical Hold on AOC 1001
Avidity Biosciences Gets Fast Track Designation for AOC 1044
Avidity's stock gains after company shares new data about partial clinical hold